Marvin Nieman

Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas.

ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation.

Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin.

Characterization of cadherin-24, a novel alternatively spliced type II cadherin.

The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1.

Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4.

Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site.

Protease-activated receptor 4 uses anionic residues to interact with alpha-thrombin in the absence or presence of protease-activated receptor 1.

AbetaPP/APLP2 family of Kunitz serine proteinase inhibitors regulate cerebral thrombosis.

Oral thrombostatin FM19 inhibits prostate cancer.

Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis.

Mapping human protease-activated receptor 4 (PAR4) homodimer interface to transmembrane helix 4.

Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation.

Calcium mobilization and protein kinase C activation downstream of protease activated receptor 4 (PAR4) is negatively regulated by PAR3 in mouse platelets.

Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by α-thrombin.

Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets.

Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race.

Race differences in platelet reactivity: is protease activated receptor 4 a predictor of response to therapy?

PARtitioning protease signaling.

Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.

Development and characterization of monoclonal antibodies against Protease Activated Receptor 4 (PAR4).

Dicer1-mediated miRNA processing shapes the mRNA profile and function of murine platelets.

Protease-activated receptors in hemostasis.

Protease-activated Receptor-4 Signaling and Trafficking Is Regulated by the Clathrin Adaptor Protein Complex-2 Independent of β-Arrestins.